OpenAI is now turning its Daybreak initiative into a defensive cybersecurity program that combines Codex updates, the GPT-5.5-Cyber release and partner access for approved organizations. As OpenAI ...

Discord and Xbox have teamed up several times over the years, usually with Xbox offering Discord Nitro perks through one of its own subscription plans, such as the Game Pass Ultimate. This time, the ...

Discord is expanding its Nitro program with more perks for subscribers. Among them is a "starter edition" of Xbox Game Pass that sounds similar to the Essential tier of the service (for those counting ...

GameSpot may receive revenue from affiliate and advertising partnerships for sharing this content and from purchases through links. Confirming earlier rumors and reports, Microsoft and Discord ...

Discord on Monday unveiled Nitro Rewards, which gives Nitro subscribers access to offers from other gaming and lifestyle brands for no additional cost. Currently, Nitro offers upgrades to Discord, ...

Nitro members will also get discounts off Logitech and SteelSeries gear. Nitro members will also get discounts off Logitech and SteelSeries gear. is a senior correspondent and author of Notepad, who ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...